BAXTER HLTHCARE CORP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BAXTER HLTHCARE CORP, and what generic alternatives to BAXTER HLTHCARE CORP drugs are available?
BAXTER HLTHCARE CORP has sixty-six approved drugs.
There are fifteen US patents protecting BAXTER HLTHCARE CORP drugs. There is one tentative approval on BAXTER HLTHCARE CORP drugs.
There are eight patent family members on BAXTER HLTHCARE CORP drugs in seven countries and one hundred and twenty-four supplementary protection certificates in fourteen countries.
Summary for BAXTER HLTHCARE CORP
| International Patents: | 8 |
| US Patents: | 15 |
| Tradenames: | 78 |
| Ingredients: | 52 |
| NDAs: | 66 |
Drugs and US Patents for BAXTER HLTHCARE CORP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | NOURESS | cysteine hydrochloride | SOLUTION;INTRAVENOUS | 212535-001 | Dec 13, 2019 | DISCN | Yes | No | 11,045,438 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Baxter Hlthcare Corp | NALOXONE HYDROCHLORIDE | naloxone hydrochloride | INJECTABLE;INJECTION | 214792-001 | Nov 7, 2022 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-001 | Nov 17, 1995 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BAXTER HLTHCARE CORP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | ZOSYN IN PLASTIC CONTAINER | piperacillin sodium; tazobactam sodium | INJECTABLE;INJECTION | 050750-001 | Feb 24, 1998 | 6,900,184 | ⤷ Sign Up |
| Baxter Hlthcare Corp | TRANSDERM SCOP | scopolamine | SYSTEM;TRANSDERMAL | 017874-001 | Approved Prior to Jan 1, 1982 | 4,262,003 | ⤷ Sign Up |
| Baxter Hlthcare Corp | DOXIL (LIPOSOMAL) | doxorubicin hydrochloride | INJECTABLE, LIPOSOMAL;INJECTION | 050718-002 | Jun 13, 2000 | 5,213,804 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BAXTER HLTHCARE CORP Drugs
Supplementary Protection Certificates for BAXTER HLTHCARE CORP Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2785706 | 2020C/516 | Belgium | ⤷ Sign Up | PRODUCT NAME: AKYNZEO - FOSNETUPITANT/PALONOSETRON; AUTHORISATION NUMBER AND DATE: EU/1/15/1001 20200318 |
| 1499331 | C300615 | Netherlands | ⤷ Sign Up | PRODUCT NAME: NATRIUMSULFAAT, MAGNESIUMSULFAAT EN KALIUMSULFAAT; NAT. REGISTRATION NO/DATE: RVG 110863 20130417; FIRST REGISTRATION: BE 434323 20130220 |
| 0788360 | SPC/GB04/021 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
